Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results https://t.co/m8N9wWZioe
RT @EiranGorodeski: Are LVADs good option for INTERMACS 4-6?: shared decision making conversation required. https://t.co/MEtFZb0Ot6 @rcstar…
RT @EiranGorodeski: Are LVADs good option for INTERMACS 4-6?: shared decision making conversation required. https://t.co/MEtFZb0Ot6 @rcstar…
RT @EiranGorodeski: Are LVADs good option for INTERMACS 4-6?: shared decision making conversation required. https://t.co/MEtFZb0Ot6 @rcstar…
Are LVADs good option for INTERMACS 4-6?: shared decision making conversation required. https://t.co/MEtFZb0Ot6 @rcstarling #HFSAExperts2017
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
RT @JACCJournals: Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https…
Risks/benefits of destination therapy LVAD w/ ROADMAP study’s 2-year outcomes! #JACCHF @rcstarling @ClevelandClinic https://t.co/prySHOvx8T https://t.co/xXvU0jqCf3
ROADMAP 2y Follow Up: Improved 6MWT with #LVAD compared to med therapy with reduced adverse events beyond 1y #JACChf https://t.co/EMIjltcQcp https://t.co/b3tfwhwAQc
Left Ventricular Assist Device better than OMT in Ambulatory Heart Failure Patients NYHA Class III - IV https://t.co/8znsMKsvO0